|
1
|
Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
|
N Engl J Med
|
2007
|
11.62
|
|
2
|
Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells.
|
Diabetes
|
2005
|
3.18
|
|
3
|
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.
|
Diabetes Care
|
2008
|
2.87
|
|
4
|
Interleukin-6 and diabetes: the good, the bad, or the indifferent?
|
Diabetes
|
2005
|
2.61
|
|
5
|
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.
|
Diabetes Care
|
2009
|
2.56
|
|
6
|
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
|
Lancet
|
2013
|
2.45
|
|
7
|
Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes.
|
J Mol Med (Berl)
|
2003
|
2.10
|
|
8
|
Role of IL-1beta in type 2 diabetes.
|
Curr Opin Endocrinol Diabetes Obes
|
2010
|
1.97
|
|
9
|
Cytokines and beta-cell biology: from concept to clinical translation.
|
Endocr Rev
|
2007
|
1.72
|
|
10
|
Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets.
|
Diabetes
|
2004
|
1.72
|
|
11
|
Poor pregnancy outcome in women with type 2 diabetes.
|
Diabetes Care
|
2005
|
1.71
|
|
12
|
Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells.
|
Diabetes
|
2009
|
1.60
|
|
13
|
Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation.
|
Diabetes
|
2011
|
1.52
|
|
14
|
Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes.
|
Diabetes Care
|
2012
|
1.46
|
|
15
|
Total mortality by elevated transferrin saturation in patients with diabetes.
|
Diabetes Care
|
2013
|
1.43
|
|
16
|
Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappaB activation.
|
Mol Endocrinol
|
2006
|
1.39
|
|
17
|
Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.
|
Mol Med
|
2011
|
1.34
|
|
18
|
RNA modifications by oxidation: a novel disease mechanism?
|
Free Radic Biol Med
|
2012
|
1.26
|
|
19
|
IAPP boosts islet macrophage IL-1 in type 2 diabetes.
|
Nat Immunol
|
2010
|
1.24
|
|
20
|
Suppressor of cytokine Signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex.
|
Mol Endocrinol
|
2006
|
1.22
|
|
21
|
TiSH--a robust and sensitive global phosphoproteomics strategy employing a combination of TiO2, SIMAC, and HILIC.
|
J Proteomics
|
2012
|
1.19
|
|
22
|
The Fas pathway is involved in pancreatic beta cell secretory function.
|
Proc Natl Acad Sci U S A
|
2007
|
1.08
|
|
23
|
The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.
|
Mol Med
|
2010
|
1.05
|
|
24
|
Elevated transferrin saturation and risk of diabetes: three population-based studies.
|
Diabetes Care
|
2011
|
1.03
|
|
25
|
The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus.
|
Nat Clin Pract Endocrinol Metab
|
2008
|
0.99
|
|
26
|
Diabetes and suppressors of cytokine signaling proteins.
|
Diabetes
|
2007
|
0.99
|
|
27
|
Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females.
|
Hum Mol Genet
|
2003
|
0.97
|
|
28
|
High glucose suppresses human islet insulin biosynthesis by inducing miR-133a leading to decreased polypyrimidine tract binding protein-expression.
|
PLoS One
|
2010
|
0.97
|
|
29
|
G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction.
|
Endocrinology
|
2009
|
0.96
|
|
30
|
Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin.
|
Diabetes Metab Res Rev
|
2013
|
0.95
|
|
31
|
Divalent metal transporter 1 regulates iron-mediated ROS and pancreatic β cell fate in response to cytokines.
|
Cell Metab
|
2012
|
0.95
|
|
32
|
Inhibition of nuclear factor-kappaB or Bax prevents endoplasmic reticulum stress- but not nitric oxide-mediated apoptosis in INS-1E cells.
|
Endocrinology
|
2009
|
0.91
|
|
33
|
Calcium has a permissive role in interleukin-1beta-induced c-jun N-terminal kinase activation in insulin-secreting cells.
|
Endocrinology
|
2005
|
0.89
|
|
34
|
Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection.
|
Proc Natl Acad Sci U S A
|
2014
|
0.88
|
|
35
|
Anti-cytokine therapies in T1D: Concepts and strategies.
|
Clin Immunol
|
2013
|
0.84
|
|
36
|
Apolipoprotein CIII reduces proinflammatory cytokine-induced apoptosis in rat pancreatic islets via the Akt prosurvival pathway.
|
Endocrinology
|
2011
|
0.84
|
|
37
|
Type 1 database mellitus: an inflammatory disease of the islet.
|
Adv Exp Med Biol
|
2004
|
0.83
|
|
38
|
Inhibition of beta cell growth and function by bone morphogenetic proteins.
|
Diabetologia
|
2014
|
0.82
|
|
39
|
Altering β-cell number through stable alteration of miR-21 and miR-34a expression.
|
Islets
|
2014
|
0.82
|
|
40
|
Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1.
|
J Biol Chem
|
2003
|
0.82
|
|
41
|
Cytokines and type 1 diabetes: a numbers game.
|
Diabetes
|
2011
|
0.82
|
|
42
|
Is puberty an accelerator of type 1 diabetes in IL6-174CC females?
|
Diabetes
|
2005
|
0.82
|
|
43
|
Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist.
|
J Neuroinflammation
|
2014
|
0.82
|
|
44
|
Transcriptional and translational regulation of cytokine signaling in inflammatory β-cell dysfunction and apoptosis.
|
Arch Biochem Biophys
|
2012
|
0.82
|
|
45
|
Suppressor of cytokine signalling-3 inhibits Tumor necrosis factor-alpha induced apoptosis and signalling in beta cells.
|
Mol Cell Endocrinol
|
2009
|
0.80
|
|
46
|
IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes.
|
Eur Cytokine Netw
|
2009
|
0.79
|
|
47
|
(19)F-heptuloses as tools for the non-invasive imaging of GLUT2-expressing cells.
|
Arch Biochem Biophys
|
2011
|
0.79
|
|
48
|
Antitumorigenic effect of proteasome inhibitors on insulinoma cells.
|
Endocrinology
|
2004
|
0.79
|
|
49
|
Total and cause-specific mortality by elevated transferrin saturation and hemochromatosis genotype in individuals with diabetes: two general population studies.
|
Diabetes Care
|
2013
|
0.78
|
|
50
|
Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy.
|
Nephron Clin Pract
|
2011
|
0.78
|
|
51
|
Helsinki alert of biodiversity and health.
|
Ann Med
|
2015
|
0.78
|
|
52
|
Direct demonstration of NCAM cis-dimerization and inhibitory effect of palmitoylation using the BRET2 technique.
|
FEBS Lett
|
2010
|
0.77
|
|
53
|
RX871024 reduces NO production but does not protect against pancreatic beta-cell death induced by proinflammatory cytokines.
|
Biochem Biophys Res Commun
|
2006
|
0.77
|
|
54
|
The lysine deacetylase inhibitor Givinostat inhibits β-cell IL-1β induced IL-1β transcription and processing.
|
Islets
|
2013
|
0.77
|
|
55
|
[Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes].
|
Ugeskr Laeger
|
2007
|
0.77
|
|
56
|
IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin.
|
Diabetes Care
|
2002
|
0.76
|
|
57
|
Skeletal muscle apolipoprotein B expression reduces muscular triglyceride accumulation.
|
Scand J Clin Lab Invest
|
2014
|
0.76
|
|
58
|
Mutation scan of a type 1 diabetes candidate gene: the human interleukin-18 binding protein gene.
|
Ann N Y Acad Sci
|
2003
|
0.76
|
|
59
|
[Insulin pumps and treatment of diabetes].
|
Ugeskr Laeger
|
2003
|
0.75
|
|
60
|
HDAC inhibitor-mediated beta-cell protection against cytokine-induced toxicity is STAT1 Tyr701 phosphorylation independent.
|
J Interferon Cytokine Res
|
2014
|
0.75
|
|
61
|
[Is there any documentation for Lyrica in the treatment of painful diabetic neuropathy?].
|
Ugeskr Laeger
|
2005
|
0.75
|
|
62
|
Leukocytoclastic vasculitis induced by subcutaneous injection of human insulin in a patient with type 1 diabetes and essential thrombocytemia.
|
Diabetes Care
|
2002
|
0.75
|
|
63
|
[Treatment of diabetes mellitus with biologic therapeutics].
|
Ugeskr Laeger
|
2008
|
0.75
|
|
64
|
Process measures and outcome research as tools for future improvement of diabetes treatment quality.
|
Diabetes Res Clin Pract
|
2002
|
0.75
|
|
65
|
[Transplantation between monozygotic twins].
|
Ugeskr Laeger
|
2004
|
0.75
|